Vistagen Therapeutics Files 8-K with Exhibits
Ticker: VTGN · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Jun 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials, exhibits
Related Tickers: VTGN
TL;DR
VTGN filed an 8-K with financial exhibits, no major news.
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on June 28, 2024, reporting an event that occurred on June 27, 2024. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates Vistagen Therapeutics is providing updated financial information and exhibits to the SEC, which could be relevant for investors monitoring the company's financial health and disclosures.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Numbers
- 000-54014 — Commission File Number (SEC filing identifier)
- 20-5093315 — IRS Employer Identification Number (Company tax identifier)
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- June 27, 2024 (date) — Earliest event date
- June 28, 2024 (date) — Filing date
- Nevada (jurisdiction) — State of incorporation
- 343 Allerton Ave. (address) — Principal executive offices
- South San Francisco, California (location) — Principal executive offices location
FAQ
What specific financial statements or exhibits are included in this 8-K filing?
The provided text states the filing includes 'Financial Statements and Exhibits' but does not list the specific documents.
What is the significance of the 'Other Events' item information?
The filing lists 'Other Events' as an item, but the specific nature of these events is not detailed in the provided excerpt.
When was Vistagen Therapeutics, Inc. incorporated?
Vistagen Therapeutics, Inc. was incorporated in Nevada.
What is the principal executive office address for Vistagen Therapeutics, Inc.?
The principal executive offices are located at 343 Allerton Ave., South San Francisco, California 94080.
Has Vistagen Therapeutics, Inc. had previous names or addresses?
Yes, the company was formerly known as VistaGen Therapeutics, Inc. and Excaliber Enterprises, Ltd., with name change dates provided.
Filing Stats: 458 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-06-28 17:29:59
Key Financial Figures
- $0.001 — ch registered Common Stock , par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn20240628_8k.htm (8-K) — 22KB
- ex_694208.htm (EX-99.1) — 12KB
- a01.jpg (GRAPHIC) — 5KB
- 0001437749-24-021626.txt ( ) — 174KB
- vtgn-20240627.xsd (EX-101.SCH) — 3KB
- vtgn-20240627_def.xml (EX-101.DEF) — 11KB
- vtgn-20240627_lab.xml (EX-101.LAB) — 15KB
- vtgn-20240627_pre.xml (EX-101.PRE) — 11KB
- vtgn20240628_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On June 27, 2024, Vistagen Therapeutics, Inc. (the " Company ") announced that it has been awarded the Mental Health America (" MHA ") 2024 Platinum Bell Seal for Workplace Mental Health, MHA's highest honor in recognition of the Company's dedication to promoting mental health and well-being in the workplace. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits . (d)Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated June 27, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: June 28, 2024 By: /s/ Shawn K. Singh Shawn K. Singh Chief Executive Officer